Dabigatran etexilate: A novel oral direct thrombin inhibitor

American Journal of Health-System Pharmacy, 08/19/2011

Dabigatran etexilate, the first oral DTI marketed in the United States, is indicated to reduce the risk of stroke and systemic embolism in patients with non–valvular atrial fibrillation. Dabigatran may be a viable option for anticoagulation in some patients due to its oral administration, rapid onset of action, and predictable anticoagulant effects.

Print Article Summary Cat 2 CME Report